ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CAC 40 Mirrors European Equities to Track Lower Wednesday as Sanofi Eyes Actelion

Share On Facebook
share on Linkedin
Print

The CAC 40 opened Wednesday lower in line with the rest of Europe’s major indices and into the afternoon is down 0.42%. With markets holding fire until this evening’s statement on the Fed on interest rate hikes and monetary policy, there seem little chance at the moment that the CAC will succeed in breaking into positive territory before the day’s conclusion. From its opening position 0.51% below yesterday’s close, the French benchmark index tracked lower in the lead-up to midday. A recovery over the past couple of hours has lost steam though and there appears to be a lack of any obvious catalyst that might pull the CAC up today.

There are no companies on the CAC today suffering particularly heavy losses and it is more a case of caution ahead of Yellen’s Fed statement on 2017 interest rate hikes which is subduing markets. An immediate 0.25% interest rate hike is considered to be a given and attention is on possible further increases throughout 2017. One the markets would likely take in their stride but the potential of an announcement of two hikes planned next year is a scenario that markets would likely react more sharply to.

Pharmaceuticals company Sanofi has fallen by the greatest margin today, recording a current loss of 2.6%. News has broken today that the French drugmaker has entered talks to acquire Europe’s largest biotech company, Switzerland’s Actelion. The Swiss had been in talks with Johnson & Johnson over a buy-out but with Americans having walked away for the second time in two years as negotiations floundered, Sanofi have stepped in. Sanofi will see the acquisition as a key part of its strategy to tackle slow growth, expiring patents and increased competition, particularly from the U.S. If the deal were to go through it would likely be worth something around the $30 billion mark.

In risers, Accor has the strongest showing so far, up 1.12%. Last week the hotel group announced an agreement to buy a 5% stake in the luxury Banyan Tree hotel brand with an option for an additional 5%.

The Singaporean group has 4 luxury hotel brands with 43 hotels and resorts between them, as well as 64 spas and 3 golf courses. The company’s assets cover 28 countries. Among the CAC’s constituents from the banking sector, Credit Agricole is 0.95% up while BNP Paribas and Societe Generale are down by 0.95% and 0.66% respectively.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This article was provided by Windsor Brokers. Click here for more information.


This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com